Boston Scientific Boosts Annual Profit Outlook on Robust Cardiac Device Sales
Boston Scientific has elevated its annual profit projections after exceeding third-quarter estimates, driven by substantial growth in heart device sales. The company’s electrophysiology segment saw a 23.1% year-over-year surge, with its stroke prevention and cardiac rhythm technologies performing particularly well. Despite facing regulatory and tariff challenges, the medical device manufacturer anticipates continued margin expansion.
Strong Cardiac Device Performance Drives Forecast Revision
Boston Scientific has reportedly raised its full-year profit guidance following better-than-expected third-quarter results, according to recent financial reports. The medical device manufacturer’s shares increased approximately 4.1% after the announcement, reflecting positive market response to the company’s performance and outlook.